Company profile: Jazz Pharmaceuticals
1.1 - Company Overview
Company description
- Provider of specialty pharmaceuticals for underserved neurology and psychiatry markets. Includes Xyrem and Xywav for cataplexy and excessive daytime sleepiness in narcolepsy; Epidiolex for seizures in Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex; Vyxeos for acute myeloid leukemia; Zepzelca for metastatic small cell lung cancer; Defitelio for hepatic veno-occlusive disease.
Products and services
- Defitelio: Post-transplant therapy indicated for hepatic veno-occlusive disease in patients after hematopoietic stem-cell transplantation, treating this condition in a transplant setting
- Epidiolex: Cannabidiol-based medication used to treat seizures associated with Lennox-Gastaut syndrome, Dravet syndrome, or Tuberous Sclerosis Complex across these defined epilepsy indications
- Vyxeos: Liposomal chemotherapy formulation of daunorubicin and cytarabine used for the treatment of acute myeloid leukemia, delivering both agents in a unified formulation
Key contacts
🔒
🔒
Financial details
🔒
1.2 - Competitors and similar companies to Jazz Pharmaceuticals
Concert Pharmaceuticals
HQ: United States
Website
- Description: Provider of clinical-stage biotechnology developing drug products via a novel precision deuterium chemistry platform, modifying specific properties of validated drug molecules to create new medicines that address patient needs, yielding a rich pipeline.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Concert Pharmaceuticals company profile →
Minerva Neurosciences
HQ: United States
Website
- Description: Provider of clinical-stage biopharmaceutical product candidates for central nervous system diseases, including roluperidone (MIN-101) for negative symptoms of schizophrenia targeting serotonin, sigma, and alpha-adrenergic receptors, and MIN-301, a recombinant neuregulin-1β1 in preclinical development for Parkinson’s disease aimed at restoring brain tissue damage and improving motor function.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Minerva Neurosciences company profile →
Coaxia
HQ: United States
Website
- Description: Provider of medical device research and development focused on therapy and treatment solutions for cerebral ischemia; based in Minneapolis, MN.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Coaxia company profile →
Semnur Pharma
HQ: United States
Website
- Description: Provider of specialty pharmaceutical development focused on the clinical and commercial advancement of innovative products for pain management, including SP-102 (SEMDEXA), a non-opioid injectable corticosteroid gel designed to treat moderate to severe chronic radicular pain/sciatica via epidural injection.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full Semnur Pharma company profile →
U.S. WorldMeds
HQ: United States
Website
- Description: Provider of specialty pharmaceutical therapies: IWILFIN, an oral maintenance therapy reducing relapse risk in high-risk neuroblastoma after prior treatment response; ZIMHI, a high-dose naloxone injection for emergency treatment of opioid overdose, effective against powerful synthetic opioids like fentanyl; and LUCEMYRA, an oral drug that mitigates opioid withdrawal to facilitate abrupt discontinuation in adults.
- Rationale: This competitor operates in a highly similar market segment with overlapping features.
- Company type: Private company
- Employees: ●●●●●
- Total funding raised: $●●●m
- Backers: ●●●●●●●●●●
- Acquisitions: ●●
View full U.S. WorldMeds company profile →
🔒
2.M&A buyers
2.1 Potential strategic acquirers in the sector
🔒
🔒
🔒
🔒
View all strategic buyers with complete profiles
Start Free Trial →
2.2 - Strategic buyer groups for Jazz Pharmaceuticals
🔒
Buyer group 1: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 2: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔒
Buyer group 3: ████████ ████████
●● companies
Description: ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████ ████████
Key Products: ████████, ████████, ████████, ████████
🔒
View all companies in this group
Request Free Trial Now →
🔓 Unlock all detailed buyer group breakdowns with complete company profiles
Start Free Trial →
3. Investors and private equity firms
3.1 - Buyout funds investing in similar companies to Jazz Pharmaceuticals
2.2 - Growth funds investing in similar companies to Jazz Pharmaceuticals
🔒
View all growth equity funds with complete profiles
Start Free Trial →
4 - Top valuation comps for Jazz Pharmaceuticals
4.2 - Public trading comparable groups for Jazz Pharmaceuticals
🔓 Unlock all public trading comparable groups with complete valuation data
Start Free Trial →